Skip to main content
Log in

Disruption of the actin cytoskeleton abolishes high affinity 3H-glibenclamide binding in rat aortic rings

  • Short communication
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

The interaction between the cytoskeleton and the ATP-sensitive K+ channel (KATP channel) was studied in rat aortic rings by examining the binding of the sulphonylurea blocker, 3H-glibenclamide, and of the opener, 3H-P1075.

The actin cytoskeleton disrupting agents, cytochalasin D (1μM) and latrunculin B (1μM), abolished the high affinity component of 3H-glibenclamide binding. Preincubation with the actin cytoskeleton stabilizing agent, phalloidin (10μM) prevented the effect of cytochalasin D. In contrast, binding of the opener, 3H-P1075, and inhibition of this binding by glibenclamide, were unaffected by cytochalasin D (3μM). Colchicine (100μM), which disassembles microtubules, had no effect on the binding of 3H-glibenclamide and 3H-P1075.

The data show that high affinity binding of glibenclamide, which mediates the effects of the sulphonylurea in this preparation, requires the presence of an intact actin cytoskeleton. Binding of the opener is unaffected by the state of the cytoskeleton and preserves a conformational state in which high affinity binding of glibenclamide to the sulphonylurea receptor can occur.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 10 October 1997 / Accepted: 21 October 1997

Rights and permissions

Reprints and permissions

About this article

Cite this article

Löffler-Walz, C., Quast, U. Disruption of the actin cytoskeleton abolishes high affinity 3H-glibenclamide binding in rat aortic rings. Naunyn-Schmiedeberg's Arch Pharmacol 357, 183–185 (1998). https://doi.org/10.1007/PL00005153

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/PL00005153

Navigation